The surgical robotics market is undergoing its most significant structural shift in over two decades. New FDA clearances for Medtronic, CMR Surgical, and Johnson & Johnson are challenging Intuitive Surgical's long-standing dominance. A Medicare reimbursement change effective January 2026 is accelerating the move of procedures into ambulatory surgery centers. The result: a market that looks fundamentally different from 2024 — and a new competitive battleground forming outside

Amid rapid scientific progress, familiar targets continue to capture momentum while promising alternatives struggle for visibility. A quiet cognitive bias shapes how opportunities are assessed and prioritized. For companies developing novel science, recognizing this pattern—and designing strategies that anticipate and counter it—will be essential to advancing differentiated programs in a landscape defined by precedent.

Federal grant volatility is disrupting early-stage biotech, with programs like CDMRP facing steep cuts and new NIH restrictions limiting access. As delays and cancellations increase, traditional budgeting falls short. This piece explores how scenario-based FP&A helps companies navigate uncertainty, prioritize pipelines, and sustain innovation in a shifting funding landscape.